Global Retirement Partners LLC Purchases New Shares in Natera, Inc. $NTRA

Global Retirement Partners LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA) during the 2nd quarter, HoldingsChannel reports. The firm purchased 5,635 shares of the medical research company’s stock, valued at approximately $1,530,000.

Other hedge funds have also added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its position in shares of Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after purchasing an additional 1,225,420 shares during the period. Wellington Management Group LLP boosted its stake in shares of Natera by 94.7% during the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares in the last quarter. State Street Corp increased its position in shares of Natera by 2.2% during the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after buying an additional 72,087 shares during the period. Coatue Management LLC increased its position in shares of Natera by 1,446.1% during the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after buying an additional 2,463,008 shares during the period. Finally, Geode Capital Management LLC raised its stake in Natera by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 2,608,644 shares of the medical research company’s stock worth $596,078,000 after buying an additional 11,689 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Price Performance

Shares of Natera stock opened at $314.18 on Tuesday. The company has a 50-day moving average of $265.78 and a 200 day moving average of $226.82. The firm has a market cap of $45.29 billion, a price-to-earnings ratio of -231.01 and a beta of 1.51. Natera, Inc. has a 1 year low of $156.71 and a 1 year high of $326.03.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. During the same period last year, the company posted ($0.74) EPS. Natera’s revenue was up 37.7% on a year-over-year basis. On average, equities analysts anticipate that Natera, Inc. will post -1.11 EPS for the current year.

Insider Buying and Selling at Natera

In related news, Director Herm Rosenman sold 16,530 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the sale, the director owned 4,250 shares in the company, valued at $1,062,500. This represents a 79.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Roelof Botha sold 78,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $220.31, for a total value of $17,184,180.00. Following the completion of the sale, the director owned 1,076,198 shares in the company, valued at $237,097,181.38. The trade was a 6.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 181,045 shares of company stock valued at $41,330,968. 5.05% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

NTRA has been the subject of several research analyst reports. Wall Street Zen lowered shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Wells Fargo & Company upped their target price on Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Sanford C. Bernstein began coverage on Natera in a research report on Friday, June 26th. They issued an “outperform” rating and a $310.00 target price for the company. Piper Sandler increased their target price on Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Finally, BTIG Research raised their target price on Natera from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $319.38.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.